Taken together these data strongly support the case that targeting SGLT2 could also inhibit the glucose-TGF-β1/ERK/Smad3 signalling cascade and subsequent key elements of renal fibrosis in our PTECs. The gene discussed is SLC5A2; the disease is renal fibrosis.